TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

Communiqués TOT BIOPHARM International Company Limited

Actions

1875

HK0000545266

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:07 05/07/2024			Varia. 5j.	Varia. 1 janv.
2 ^HKD	+1,52%		-8,68%	+1,52%

15/03	TOT BIOPHARM International Company Limited annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	La perte de TOT Biopharm se réduit au premier semestre	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOP BIOPHARM Shares	01/06/22	AQ
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China	02/12/21	PR
TOT BIOPHARM International : 2021 Interim Revenue Surges 78% to RMB23.13 million	13/08/21	AQ
TOT BIOPHARM International : VOLUNTARY ANNOUNCEMENT - MARKETING APPROVAL FOR MEGESTROL ACETATE ORAL SUSPENSION (TOM218) OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	13/05/21	PU
TOT BIOPHARM International : CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2021	10/05/21	PU
TOT BIOPHARM International : Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020	23/03/21	AQ
TOT BIOPHARM International : Optimises Company Management Structure to Promote Strategic Development Upgrade	16/10/20	AQ
TOT BIOPHARM International : INTERIM REPORT 2020	21/09/20	PU
Form of proxy for use by shareholders at the extraordinary general meeting to be held with the combination of a physical meeting at Unit 1603-1604, 16/F, Causeway Bay Plaza I, 489 Hennessy Road, Causeway Bay, Hong Kong and a virtual meeting online on Friday, 21 August 2020 at 4:00 p.m. (or any adjournment thereof)	31/07/20	PU
TOT BIOPHARM International : VOLUNTARY ANNOUNCEMENT - COMPLETION OF DOSING IN THE FIRST PATIENT FOR THE PHASE III CLINICAL TRIAL OF TAA013, AN ANTIBODY DRUG CONJUGATE	23/07/20	PU
TOT BIOPHARM International : Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial	22/04/20	AQ
TOT BIOPHARM International : Announces 2019 Annual Results	18/03/20	AQ
TOT BIOPHARM International : Garners "Listing Award of Technological Company" and "Innovative Technological Research and Development Award"	09/03/20	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Bourse
Actions
Action 1875
Actualités TOT BIOPHARM International Company Limited
Communiqués

Nos Contenus Gratuits vous Aident à Sécuriser et Augmenter la Performance de vos Investissements

Sécuriser mes Investissements

fermer